Caldera Therapeutics Reports CLD-423 Phase 1a Data
The company also expanded its immunology and inflammation pipeline with an anti-IL-17 x TL1A bispecific antibody program. The available body text says the CLD-423 data demonstrated favorable tolerability and immunogenicity.